Bendamustine and its role in the treatment of unfit patients with chronic lymphocytic leukaemia: a perspective review.

ABSTRACT: With a median age of 72 years at first diagnosis, chronic lymphocytic leukaemia (CLL) is a disease of the elderly. At this age, many patients cannot bear an intensive chemoimmunotherapy like fludarabine, cyclophosphamide and rituximab (FCR), and therapeutic decisions are commonly complicated by a high burden of accompanying comorbidities. Clinical trials, on the other hand, are mostly designed to include a far healthier and younger trial population, with a median age in most studies well below 70 years, leading to an insufficient reflection of clinical reality. With the introduction of new targeted therapies, treatment of CLL is currently undergoing a profound change. New compounds like ibrutinib or idelalisib have enlarged the therapeutic options in treating CLL. However, so far, these or

SUBMITTER: Al-Sawaf O 

PROVIDER: S-EPMC5424860 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature